Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultrasound-guided TAP Block Vs Local Wound Infiltration for Analgesia After Cesarean Section.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04711096
Recruitment Status : Recruiting
First Posted : January 15, 2021
Last Update Posted : January 19, 2021
Sponsor:
Information provided by (Responsible Party):
Mostafa R Bakry, Master's Degree, Ain Shams Maternity Hospital

Brief Summary:

Adequate pain control after cesarean delivery is a major concern for both parturients and obstetrician, and it usually comprise a combination of systemic and regional techniques. The transversus abdominis plane (TAP) block, affecting the nerves supplying the anterior abdominal wall, is a recently introduced, promising regional analgesic technique for a variety of abdominal and pelvic surgeries including cesarean delivery .

Infiltration of local anesthetic into the surgical wound (either as a single shot or using indwelling catheters) has long been used for postoperative analgesia, Both the TAP block and wound infiltration, are superior to placebo, however, it is unknown which of them provides better analgesia after cesarean delivery because of a scarcity of randomized clinical trials.

This study aimed to compare bilateral US guidedTAP block with single-shot local anesthetic wound infiltration for analgesia after cesarean delivery performed under general anesthesia. The investigators hypothesized that the TAP block would decrease postoperative cumulative opioid consumption at 24 hours.


Condition or disease Intervention/treatment
Postoperative Pain Control Procedure: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.

Show Show detailed description

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Days
Official Title: Ultrasound-guided Transversus Abdominis Plane (TAP) Block Versus Local Wound Infiltration for Post-operative Analgesia After Cesarean Section Under General Anesthesia.
Actual Study Start Date : January 1, 2021
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Group A
TAB group formed of 65 patients
Procedure: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.
After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
Other Name: local wound infiltration

Group B

Group B : The Infiltration Group formed of 65 patients.

• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin.

Procedure: Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.
After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
Other Name: local wound infiltration

Group C

Group C : Narcotics only group formed of 20 patients

• routine analgesic was taken only without any intervention




Primary Outcome Measures :
  1. Postoperative pain severity assessed by the Numerical Rating Scale (NRS) pain score at 1,2,4,6, 12, and 24 hours [ Time Frame: 24 hours after the procedure ]
    Assessment of pain involves asking a patient to rate her pain from 0 to 10 (11 point scale) with the understanding that 0 is equal to no pain and 10 equal to the worst possible pain after first hour, 2nd hour,4th hour, 6th hour, 12th hour and 24th hour at wards after end of surgery.

  2. The duration of analgesia achieved by each type of block assessed by the time of first postoperative pethidine dose required. [ Time Frame: 24 hours after the procedure ]
    By asking the patients about the first time to analgesic request


Secondary Outcome Measures :
  1. Cumulative pethidine consumption at 2, 4, 6, and 12 hours, NRS at 0, 4, 6, 12, and 24 hours. [ Time Frame: 24 hours after the procedure ]
    By observation of first time to analgesia requested.

  2. the incidence of side effects and Toxicity (nausea and vomiting and pruritis). [ Time Frame: 24 hours after the procedure ]
    Observation of vital data in the first 24 hours postoperatively.

  3. Patient Satisfaction [ Time Frame: 24 hours after the procedure ]
    Patient satisfaction from postoperative analgesia will be assessed at 24 hours postoperatively using a 5-point scale (1 = very unsatisfied, 2 = unsatisfied, 3 = fair, 4 = satisfied,and 5 = very satisfied) after first hour, 2nd hour,4th hour, 6th hour, 12th hour and 24th hour at wards after end of surgery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study subjects will randomly assigned to 3 equal groups (TAP group and infiltration group and Narcotics only group) of patients undergoing elective cesarean section under general anathesia in Ain Shams Maternity hospital
Criteria

Inclusion Criteria:

  • • Patients undergoing elective cesarean section under general anathesia

    • Pfannenstiel Skin Incision
    • Age between 18 and 40 years old
    • BMI between 18 and 35 kg/m2

Exclusion Criteria:

  • • Patient refusal.

    • BMI<18 kg/m2 or>35 (require different dose of analgesia)
    • Height <150 or > 180 cm (require different dose of analgesia)
    • Patients with any neurological deficit due to neuropathy and pain score affection
    • Patients with bleeding disorders which may lead to hematoma
    • HTN (Vasculopathy which can lead to hematoma).
    • Cardiac disease ( Vasculopathy on anticoagulant which can lead to hematoma)
    • DM (decrease systemic and local immunity which can lead to abscess at injection site and due to neuropathy and pain score affection).
    • Liver disease (defective clotting factors).
    • A history of relevant drug allergy or Hypersensitivity to any of the drugs used in the study due to impair of proper follow up of pain postoperative
    • History of recent opioid exposure due to affection on pain score
    • Local skin infection due to abscess formation
    • Obstetric complications e.g placenta previa and rupture uterus due to extensive tissue damage and dissection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04711096


Contacts
Layout table for location contacts
Contact: Mostafa Bakry, Master 01008618768 MostafaBakry9090@gmail.com
Contact: Rehab Abdel Rahman, Prof 01004992772 Rehababdulrahman.rm@gmail.com

Locations
Layout table for location information
Egypt
Ain Shams University Maternity Hospital Recruiting
Cairo, Egypt, 11865
Contact: Mostafa Bakry, Master's    01008618768    MostafaBakry9090@gmail.com   
Contact: Rehab Abdelrahman, MD    01004992772    Rehababdulrahman.rm@gmail.com   
Principal Investigator: Ahmed Ramy, Prof         
Principal Investigator: Mostafa Bakry, Master's         
Principal Investigator: Rehab Abdel Rahman, MD         
Principal Investigator: Ahmed Gamal Abdel Nasser, MD         
Principal Investigator: Mohamed Maher Elwarraky, MD         
Sponsors and Collaborators
Ain Shams Maternity Hospital
Investigators
Layout table for investigator information
Study Director: Rehab Abdel Rahman, Prof Ain Shams Maternity Hospital
Publications of Results:

Layout table for additonal information
Responsible Party: Mostafa R Bakry, Master's Degree, The principal investigator, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier: NCT04711096    
Other Study ID Numbers: Post Cesarean TAP Block
First Posted: January 15, 2021    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mostafa R Bakry, Master's Degree, Ain Shams Maternity Hospital:
Post Cesarean TAP Block
TAB block
Postoperative Pain control
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Bupivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents